Drugs / Mecapegfilgrastim
Mecapegfilgrastim
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 27 trials · 1 met primary | ||||||
| Phase 2 | NCT07205536 | Aug 2025 → Dec 2027 expected | bone marrow failure syndrome, neoplasm of thorax | Affiliated Hospital of Nantong University | Recruiting | No outcome recorded |
| Phase 2 | NCT06684158 | Nov 2024 → Mar 2027 expected | gastroesophageal junction adenocarcinoma | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05463601 | Aug 2022 → Jan 2025 overdue | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05076682 | Jun 2022 → Dec 2026 expected | triple-negative breast carcinoma | Fudan University | Recruiting | Met primary |
| Phase 2 | NCT05294055 | Apr 2022 → Mar 2026 overdue | plasma cell myeloma | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT05222035 | Jan → Dec 2022 | — | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT04460508 | Dec 2020 → Dec 2022 | lymphoma, neutropenia | The First Hospital of Jilin University | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06254742 | Feb 2024 → Jul 2025 | chemotherapy-induced toxicity | Jiangsu HengRui Medicine Co., Ltd. | Withdrawn | No outcome recorded Stop: Business |
| Phase not applicable1 trial | ||||||
| — | NCT04171986 | Nov 2019 → Oct 2021 | small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06037655 Background | Sep 2023 → Mar 2026 overdue | biliary tract neoplasm | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mecapegfilgrastim | “This study is to evaluate efficacy and safety in chemotherapy-induced neutropenia of once-per-cycle Mecapegfilgrastim Injection(PEG-G-CSF) and daily G-CSF in Patients with...” NCT04460508 ↗8“G-CSF: mecapegfilgrastim, 6 mg, subcutaneous injection, Day 1, Q3W, until stop using Camrelizumab, progressive disease (PD) or unacceptable toxicity.” NCT05222035 ↗ “Mecapegfilgrastim (6 mg) every three weeks intravenously” NCT06037655 ↗ |
| Known as | HHPG-19K | “Mecapegfilgramtim (code name HHPG-19K), a long-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF), has been developed.” NCT05463601 ↗ |
| Known as | PEG-G-CSF | “This study is to evaluate efficacy and safety in chemotherapy-induced neutropenia of once-per-cycle Mecapegfilgrastim Injection(PEG-G-CSF) and daily G-CSF in Patients with...” NCT04460508 ↗ |
| Modality | Protein / enzyme biologic | “A newly pegylated rhG-CSF was independently developed by JIANGSU HENGRUI Medicine Co., Ltd, China.” NCT04460508 ↗ |
| Route | Subcutaneous | “s.c.” NCT05076682 ↗ |